UT MD Anderson, GlaxoSmithKline to Collaborate on New Approach to Cancer Immune Therapy; Success Could Earn Cancer Center $335 Million Plus Royalties
Friday, December 7, 2012 - 08:31
in Health & Medicine
The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.